Side-by-side · Research reference
BPC-157vsPEG-MGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED9/53 cited
BAnimal-MechanisticHUMAN-REVIEWED2/69 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
01Mechanism of Action
Parameter
BPC-157
PEG-MGF
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011Sikiric 2018
IGF-1 receptor on muscle satellite cells and myocytes
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Partially bypassed — does not require hepatic IGF-1 synthesis
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Antibody development
—
Unknown — no long-term human immunogenicity data
02Dosage Protocols
Parameter
BPC-157
PEG-MGF
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
—
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Lower / starter dose
200 mcg / day
Conservative starter for new users.
—
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
—
Reconstitution
Bacteriostatic water, 1–2 mL
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Within 30–60 min post-training
Aligns with endogenous MGF window.
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
Research dose range
—
100–200 mcg
Extrapolated from animal models; no validated human protocols.
PEG molecular weight
—
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
03Metabolic / Fat Loss Evidence
Parameter
BPC-157
PEG-MGF
Primary target
—
Muscle tissue (satellite cells, myocytes) — not adipose-specific
Indirect metabolic effect
—
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
Body composition
—
Lean mass preservation / hypertrophy focus
Fat loss evidence
—
No direct human or animal RCT data for PEG-MGF-driven fat reduction
04Side Effects & Safety
Parameter
BPC-157
PEG-MGF
Injection site reaction
Mild irritation (anecdotal)
Erythema, induration (common with SQ peptides)
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Cancer risk
Theoretical concern via VEGF angiogenesis pathwaySikiric 2018
IGF-1 axis stimulation contraindicated in active malignancy
Antibody formation
No data (no long-term human trials)
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
Pregnancy / OB
Avoid — insufficient safety data
—
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Hypoglycemia risk
—
IGF-1 axis activation can lower blood glucose
IGF-1R overstimulation
—
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
Fluid retention
—
Possible with IGF-1 pathway activation (dose-dependent)
PEG accumulation
—
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
Human safety data
—
Absent — no published human trials for PEG-MGF
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
05Administration Protocol
Parameter
BPC-157
PEG-MGF
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair